Schoch Bradley S, Werner Brian C, Shapiro Shane A, Camp Christopher L, Chalmers Peter N, Cancienne Jourdan M
Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, USA.
Orthop J Sports Med. 2022 Nov 3;10(11):23259671221127004. doi: 10.1177/23259671221127004. eCollection 2022 Nov.
The application of orthobiologics at the time of arthroscopic rotator cuff repair (RCR) has received an increasing amount of clinical interest despite a relative scarcity of human clinical studies on their efficacy.
To utilize a national administrative database to determine the association of bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP) applied at the time of RCR with revision surgery rates.
Cohort study; Level of evidence, 3.
The Mariner data set from the PearlDiver patient records repository was utilized to identify patients undergoing RCR using Current Procedural Terminology (CPT) code 29827. Patients receiving BMAC or PRP at the time of RCR were then identified using CPT coding. For comparison purposes, a matched cohort was created consisting of patients who underwent RCR without biologic augmentation in a 5:1 fashion for each biologic separately. Cases were matched according to age, sex, tobacco use, biceps tenodesis, distal clavicle excision, and subacromial decompression. All groups were then queried for revision RCR or conversion to reverse shoulder arthroplasty. Revision rates were compared utilizing a multivariate binomial logistic regression analysis. Adjusted odds ratios (ORs) and 95% CIs were calculated.
A total of 760 patients who underwent biologic augmentation during RCR were identified, including 646 patients in the PRP group and 114 patients in the BMAC group. They were compared with 3800 matched controls without documented biologic application at the time of surgery. Compared with matched controls, patients who received BMAC at the time of surgery experienced a significantly lower incidence of revision surgery at 2 years (OR, 0.36; 95% CI, 0.15-0.82; = .015). There was no significant difference in revision rates between PRP and matched controls (OR, 0.87; 95% CI, 0.62-1.23; = .183).
The application of BMAC at the time of RCR was associated with a significant decrease in the incidence of revision surgery. There was no apparent effect of PRP on the incidence of revision surgery after primary RCR. Higher-level clinical studies considering surgical factors are needed to more clearly define the role of biologic adjuvants in RCR.
尽管关于关节镜下肩袖修复术(RCR)时使用骨科生物制剂的疗效的人体临床研究相对较少,但该生物制剂在关节镜下肩袖修复术(RCR)中的应用已引起越来越多的临床关注。
利用国家行政数据库确定RCR时应用骨髓抽吸浓缩物(BMAC)和富血小板血浆(PRP)与翻修手术率之间的关联。
队列研究;证据等级,3级。
利用PearlDiver患者记录库中的Mariner数据集,通过当前手术操作术语(CPT)代码29827识别接受RCR的患者。然后使用CPT编码识别在RCR时接受BMAC或PRP的患者。为了进行比较,分别以5:1的比例为每种生物制剂创建了一个由未进行生物增强的RCR患者组成的匹配队列。根据年龄、性别、吸烟情况、肱二头肌固定术、锁骨远端切除术和肩峰下减压术进行病例匹配。然后查询所有组的翻修RCR或转换为反向肩关节置换术的情况。使用多变量二项逻辑回归分析比较翻修率。计算调整后的优势比(OR)和95%可信区间(CI)。
共识别出760例在RCR期间接受生物增强的患者,其中PRP组646例,BMAC组114例。将他们与3800例手术时未记录使用生物制剂的匹配对照组进行比较。与匹配对照组相比,手术时接受BMAC的患者在2年时翻修手术的发生率显著较低(OR,0.36;95%CI,0.15 - 0.82;P = 0.015)。PRP组与匹配对照组的翻修率无显著差异(OR,0.87;95%CI,0.62 - 1.23;P = 0.183)。
RCR时应用BMAC与翻修手术发生率显著降低相关。PRP对初次RCR后的翻修手术发生率无明显影响。需要开展考虑手术因素的更高水平临床研究,以更明确生物佐剂在RCR中的作用。